Gemini Therapeutics develops first‑in‑class therapeutics matched to molecular abnormalities found in patients with genetically‑defined dry AMD and related rare diseases. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company focuses on patients with high genetic risk profiles and targets regulatory proteins in the complement system. Gemini leverages academic collaborations and exclusive technology from the University of Edinburgh, Newcastle University, the Sanquin Blood Supply Foundation and industry partners including StrideBio. Leadership and scientific founders span academic experts in retinal disease, target biology and gene therapy. The company announced a $42.5 million Series A to advance multiple programs toward the clinic.

Total raised

$43M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2017